A5001291478- Gestational Trophoblastic Disease Studies
- Prenatal Screening and Diagnostics
- Ectopic Pregnancy Diagnosis and Management
- Maternal and fetal healthcare
- Congenital Diaphragmatic Hernia Studies
- Pregnancy and preeclampsia studies
- Lung Cancer Research Studies
- Social Media and Politics
- Cancer Mechanisms and Therapy
- Genetic Syndromes and Imprinting
- Testicular diseases and treatments
- Ovarian cancer diagnosis and treatment
- Peptidase Inhibition and Analysis
- Cancer therapeutics and mechanisms
- Neuropeptides and Animal Physiology
- PI3K/AKT/mTOR signaling in cancer
- Epigenetics and DNA Methylation
- Teratomas and Epidermoid Cysts
- Neuroendocrine regulation and behavior
- Hypothalamic control of reproductive hormones
- Peripheral Neuropathies and Disorders
- Neonatal Respiratory Health Research
- Biochemical and Molecular Research
- Polyomavirus and related diseases
- Gestational Diabetes Research and Management
Imperial College London
2016-2025
Charing Cross Hospital
2016-2025
Imperial College Healthcare NHS Trust
2012-2024
Hammersmith Hospital
2006-2020
National Health Service
2012-2019
BC Cancer Agency
2014-2017
Simon Fraser University
2017
Imperial Valley College
2017
National Institute for Health Research
2015
Norwegian Womens Public Health Association
2015
Gestational trophoblastic disease (GTD) arises from abnormal placenta and is composed of a spectrum premalignant to malignant disorders. Changes in epidemiology GTD have been noted various countries. In addition histology, molecular genetic studies can help the diagnostic pathway. Earlier detection molar pregnancy by ultrasound has resulted changes clinical presentation decreased morbidity uterine evacuation. Follow-up with human chorionic gonadotropin (hCG) essential for early diagnosis...
Gestational trophoblastic disease (GTD) is a group of uncommon conditions associated with abnormal pregnancy. Histologically, it includes the benign partial and complete hydatidiform mole, invasive metastatic as well malignant choriocarcinoma, placental site tumor (PSTT), epithelioid (ETT). Molar pregnancies may develop persistent elevated serum human chorionic gonadotropin (hCG) levels after evacuation (complete mole 15%−20%, 0.1%−5% [1–3]), chance progression to choriocarcinoma that...
Gestational trophoblastic disease (GTD) arises from abnormal placenta and is composed of a spectrum premalignant to malignant disorders. Changes in epidemiology GTD have been noted various countries. In addition histology, molecular genetic studies can help the diagnostic pathway. Earlier detection molar pregnancy by ultrasound has resulted changes clinical presentation decreased morbidity uterine evacuation. Follow-up with human chorionic gonadotropin (hCG) essential for early diagnosis...
We have simplified the treatment of gestational trophoblastic disease (GTD) in order to reduce number patients exposed potentially carcinogenic chemotherapy. Patients who score 0 8 on Charing Cross scoring system are classified as low-risk and receive methotrexate (MTX) folinic acid (FA), whereas those higher than high-risk etoposide, methotrexate, dactinomycin (EMA)/cyclophosphamide vincristine (CO) regimen.Between 1992 2000, 485 women with GTD were commenced MTX/FA at Hospital, London,...
To determine pregnancy outcome, including the rate of repeat molar pregnancy, following histologically confirmed complete or partial hydatidiform mole.Retrospective review a large supraregional database registrations for gestational trophoblastic disease.Supraregional Trophoblastic Disease Unit, London.Women with pregnancies affected by mole registered between 1992 and 1998.All patients diagnosis were identified data on subsequent compared groups using comparison proportion test.Pregnancy...
To examine the accuracy of sonographic findings routine ultrasound examinations in patients with a proven histological diagnosis complete or partial hydatidiform mole referred to supra-regional referral center, and relationship gestational age across first early second trimesters.Review consecutive cases trophoblastic disease unit from June 2002 January 2005 possible probable whom results pre-evacuation examination were documented. Ultrasound detection rates for moles calculated comparison...
Patients with high-risk (International Federation of Gynecology and Obstetrics score ≥ 7) gestational trophoblastic neoplasia (GTN) frequently receive etoposide, methotrexate, dactinomycin alternating weekly cyclophosphamide vincristine (EMA/CO). Between 1979 1995, overall survival (OS) this regimen at our institute was 85.4% a significant proportion early deaths (< 4 weeks). Here, we determine whether rates have improved in more recent patient cohort (1995 to 2010).Patients receiving EMA/CO...
The national registration and treatment service for molar pregnancies in the UK allows collection of accurate data on this relatively rare diagnosis. In England Wales, between 2000 2009, 5,793 patients with complete moles 7,790 partial were registered, compared a total 8,242,511 conceptions. overall pregnancy incidence was 1 every 607 conceptions (complete mole 1:1,423; 1:1,058), but major variations age. For moles, risk varied from < 1:1,000 ages 18-40, to 1:156 women aged 45 1:8 those 50...
Pseudo‐partial moles: placental stem vessel hydrops and the association with Beckwith–Wiedemann syndrome complete moles Aims : To describe clinical histological features of a series cases placentas originally diagnosed as partial in which final diagnosis was that villous hydrops, mesenchymal dysplasia or syndrome. Methods results We searched computerized database containing suspected proven trophoblastic disease examined at Trophoblastic Disease Unit Charing Cross Hospital, London, to...
The majority of women requiring chemotherapy for gestational trophoblastic disease (GTN) are cured with their initial treatment. However, a small percentage either become refractory to treatment, or relapse after the completion This study investigates characteristics and outcome these patients. Patients were identified from Charing Cross Hospital GTD database. patients relapsed was compared those disease. Between 1980 2004, 1708 treated GTN. Sixty (3.5%) patents following therapy. overall...
The WHO Classification of Gestational Trophoblastic Tumors classifies placental site nodule (PSN) as a benign tumor-like trophoblastic neoplasm. Cases PSN with atypical features were described [atypical (APSN)] and we started registering APSN in our unit 2005. aim this study is to present initial experience these lesions. Disease Unit database was searched identify all patients who either referred with, or on review diagnosed from September 2005 May 2013. Case notes the pathology findings...
Gestational trophoblastic neoplasia (GTN) after a hydatidiform mole is either treated with single- or multi-agent chemotherapy determined by multifactorial scoring system. Women human chorionic gonadotrophin (hCG) levels >100 000 IU l−1 can remain within the low-risk/single-agent category and usually choose one drug therapy. Here we compare success duration of vs in this patient group. Between 1980 2008, 65 women had pre-treatment hCG were low risk. The initial level, treatment regimens,...